4.3 Review

Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment

期刊

JOURNAL OF ONCOLOGY
卷 2013, 期 -, 页码 -

出版社

HINDAWI LTD
DOI: 10.1155/2013/183602

关键词

-

类别

资金

  1. Associazione Italiana per la Ricerca sul Cancro (AIRC)
  2. Investigator Grant and Special Program Molecular Clinical Oncology 5 per thousand, Milan [9965]
  3. European Commission's Seventh Framework Programme (EU/FP7) [278706]
  4. Ministry of Health, Rome, Italy

向作者/读者索取更多资源

Tumor microenvironment is essential for multiple myeloma (MM) growth, progression, and drug resistance through provision of survival signals and secretion of growth and proangiogenic factors. This paper examines the importance of macrophages within MM bone marrow (BM) microenvironment, referred to as MM-associated macrophages, as a potential niche component that supports tumor plasma cells. These macrophages are derived from peripheral blood monocytes recruited into the tumor. Upon activation by MM plasma cells and mesenchymal stromal cells, macrophages can release growth factors, proteolytic enzymes, cytokines, and inflammatory mediators that promote plasma cell growth and survival. Macrophages promote tumor progression through several mechanisms including angiogenesis, growth, and drug resistance. Indeed, these macrophages are essential for the induction of an angiogenic response through vasculogenic mimicry, and this ability proceeds in step with progression of the plasma cell tumors. Data suggest that macrophages play an important role in the biology and survival of patients with MM, and they may be a target for the MM antivascular management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, Research & Experimental

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis

Antonio Giovanni Solimando, Nicola Susca, Antonella Argentiero, Oronzo Brunetti, Patrizia Leone, Valli De Re, Rossella Fasano, Markus Krebs, Elisabetta Petracci, Irene Azzali, Oriana Nanni, Nicola Silvestris, Angelo Vacca, Vito Racanelli

Summary: A meta-analysis of second-line therapies for hepatocellular carcinoma (HCC) identified regorafenib and cabozantinib as potential treatment options, showing significant improvement in overall survival and progression-free survival compared with placebo in randomized controlled trials. None of the compared drugs stood out as clearly superior after stratification of patients.

CLINICAL AND EXPERIMENTAL MEDICINE (2022)

Article Ophthalmology

The Spectrum of Ocular Manifestations in Patients with Waldenstrom's Macroglobulinemia

Rosanna Dammacco, Walter Lisch, Tero T. Kivela, Evangelos Terpos, Efstathios Kastritis, Dario Sisto, Alberto Mavilio, Roberto Ria, Giovanni Alessio, Angelo Vacca, Franco Dammacco

Summary: The study investigated the ocular manifestations in 91 Waldenstrom's macroglobulinemia (WM) patients, revealing a variety of ocular impairments that can potentially threaten vision. Genetic analysis and treatment have significantly improved ophthalmological outcomes, highlighting the importance of managing both the hematological and ocular aspects of WM patients.

OCULAR IMMUNOLOGY AND INFLAMMATION (2022)

Article Rheumatology

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, Vincent Cottin, Franco Franceschini, Stefano Del Giacco, Franco Schiavon, Thomas Neumann, Giuseppe Lopalco, Pavel Novikov, Chiara Baldini, Carlo Lombardi, Alvise Berti, Federico Alberici, Marco Folci, Simone Negrini, Renato Alberto Sinico, Luca Quartuccio, Claudio Lunardi, Paola Parronchi, Frank Moosig, Georgina Espigol-Frigole, Jan Schroeder, Anna Luise Kernder, Sara Monti, Ettore Silvagni, Claudia Crimi, Francesco Cinetto, Paolo Fraticelli, Dario Roccatello, Angelo Vacca, Aladdin J. Mohammad, Bernhard Hellmich, Maxime Samson, Elena Bargagli, Jan Willem Cohen Tervaert, Camillo Ribi, Davide Fiori, Federica Bello, Filippo Fagni, Luca Moroni, Giuseppe Alvise Ramirez, Mouhamad Nasser, Chiara Marvisi, Paola Toniati, Davide Firinu, Roberto Padoan, Allyson Egan, Benjamin Seeliger, Florenzo Iannone, Carlo Salvarani, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi

Summary: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks proved effective in treating EGPA, with no significant difference between the two doses. Complete response rates reached 30.4% at 12 months and 35.7% at 24 months, with some patients experiencing exacerbations in asthma and ENT.

ARTHRITIS & RHEUMATOLOGY (2022)

Article Hematology

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Cirino Botta, Antonella Bruzzese, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Antonino Neri, Nicola Di Renzo, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Massimo Gentile

Summary: The non-randomized comparison between KRd and EloRd therapies in relapsed/refractory multiple myeloma patients showed that KRd treatment led to a higher probability of achieving a CR+VGPR response, reduced progression or death risk, and had a greater effect on patients achieving CR+VGPR compared to those achieving < VGPR. The overall results suggest potential benefits of KRd therapy over EloRd in clinical practice.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Article Oncology

Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs

Ilaria Saltarella, Aurelia Lamanuzzi, Vanessa Desantis, Lucia Di Marzo, Assunta Melaccio, Paola Curci, Tiziana Annese, Beatrice Nico, Antonio Giovanni Solimando, Giulia Bartoli, Doron Tolomeo, Clelia Tiziana Storlazzi, Maria Addolorata Mariggio, Roberto Ria, Pellegrino Musto, Angelo Vacca, Maria Antonia Frassanito

Summary: The crosstalk between multiple myeloma cells and bone marrow fibroblasts plays a crucial role in disease progression and drug resistance. Researchers have found that MM cell-derived exosomes can reprogram the miRNA profile of fibroblasts, and tumor cells can neutralize exosomal miRs through lncRNA expression to ensure their survival.

JOURNAL OF PATHOLOGY (2022)

Review Biochemistry & Molecular Biology

Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives

Ilaria Saltarella, Concetta Altamura, Aurelia Lamanuzzi, Benedetta Apollonio, Angelo Vacca, Maria Antonia Frassanito, Jean-Francois Desaphy

Summary: Ion channels play a critical role in multiple myeloma by modulating intracellular pathways that promote tumor cell survival, proliferation, and drug resistance, making them a potential therapeutic target for MM treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Medicine, General & Internal

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance

Assunta Melaccio, Antonia Reale, Ilaria Saltarella, Vanessa Desantis, Aurelia Lamanuzzi, Sebastiano Cicco, Maria Antonia Frassanito, Angelo Vacca, Roberto Ria

Summary: Multiple myeloma (MM) is an incurable hematological malignancy. Researchers are actively searching for early and non-invasive biomarkers to predict clinical outcomes and therapeutic responses. The interaction between malignant plasma cells and bone marrow stromal cells plays a crucial role in MM progression. This article discusses the roles of cytokines and growth factors in the pathogenesis of MM and their potential as prognostic and predictive biomarkers. It also explores the potential of targeted drugs that can simultaneously block plasma cell proliferation and survival, plasma cell-bone marrow stromal cell interactions, and bone marrow stromal cell activity, which may be the future goal of MM therapy.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Biochemistry & Molecular Biology

SARS-CoV-2 and Skin: New Insights and Perspectives

Gerardo Cazzato, Eliano Cascardi, Anna Colagrande, Caterina Foti, Alessandra Stellacci, Maricla Marrone, Giuseppe Ingravallo, Francesca Arezzo, Vera Loizzi, Antonio Giovanni Solimando, Paola Parente, Eugenio Maiorano, Gennaro Cormio, Angelo Vacca, Leonardo Resta

Summary: The SARS-CoV-2 pandemic has disrupted global health systems and brought the entire globe to its knees. Although born as a disease of the respiratory system, COVID-19 can affect different parts of the body, including the skin. Researchers conducted immunohistochemical investigations and literature reviews to investigate the association between SARS-CoV-2, ACE2, TMPRSS2, and skin manifestations. They found no statistically significant differences in the immune expression of ACE2 and TMPRSS2 between SARS-CoV-2-positive patients and healthy controls. ACE2 appears to be a target of SARS-CoV-2, and further studies are needed to understand the mechanisms underlying skin manifestations.

BIOMOLECULES (2022)

Review Biochemistry & Molecular Biology

microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation

Vanessa Desantis, Maria Assunta Potenza, Luca Sgarra, Carmela Nacci, Antonietta Scaringella, Sebastiano Cicco, Antonio Giovanni Solimando, Angelo Vacca, Monica Montagnani

Summary: The pathophysiology of atrial fibrillation (AF) may involve atrial fibrosis/remodeling and dysfunctional endothelial activities. miRNAs regulate gene expression at the post-transcriptional level and may represent novel and attractive biomarker candidates in AF due to their ease of accessibility in biofluids and prognostic and diagnostic properties.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Oncology

Anti-Angiogenic Activity of Drugs in Multiple Myeloma

Ilaria Saltarella, Concetta Altamura, Carmen Campanale, Paola Laghetti, Angelo Vacca, Maria Antonia Frassanito, Jean-Francois Desaphy

Summary: Angiogenesis is a critical factor in multiple myeloma, affecting patients' prognosis, survival, and drug resistance. Various anti-angiogenic drugs targeting angiogenic cytokines and their receptors have been developed, along with standard antimyeloma drugs that also exhibit anti-angiogenic effects. This review examines the pharmacological profile and in vitro and in vivo anti-angiogenic effects of these therapies. Although direct targeting of angiogenic cytokines/receptors has shown limited efficacy, there is a need for a deeper understanding of the bone marrow angiogenic niche to develop novel multi-targeting anti-angiogenic therapies.

CANCERS (2023)

Article Health Care Sciences & Services

Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)

Margherita Zen, Mariele Gatto, Roberto Depascale, Francesca Regola, Micaela Fredi, Laura Andreoli, Franco Franceschini, Maria Letizia Urban, Giacomo Emmi, Fulvia Ceccarelli, Fabrizio Conti, Alessandra Bortoluzzi, Marcello Govoni, Chiara Tani, Marta Mosca, Tania Ubiali, Maria Gerosa, Enrica P. Bozzolo, Valentina Canti, Paolo Cardinaletti, Armando Gabrielli, Giacomo Tanti, Elisa Gremese, Ginevra De Marchi, Salvatore De Vita, Serena Fasano, Francesco Ciccia, Giulia Pazzola, Carlo Salvarani, Simone Negrini, Andrea Di Matteo, Rossella De Angelis, Giovanni Orsolini, Maurizio Rossini, Paola Faggioli, Antonella Laria, Matteo Piga, Alberto Cauli, Salvatore Scarpato, Francesca Wanda Rossi, Amato De Paulis, Enrico Brunetta, Angela Ceribelli, Carlo Selmi, Marcella Prete, Vito Racanelli, Angelo Vacca, Elena Bartoloni, Roberto Gerli, Elisabetta Zanatta, Maddalena Larosa, Francesca Saccon, Andrea Doria, Luca Iaccarino

Summary: This study assessed the efficacy of belimumab in treating joint and skin manifestations in a nationwide cohort of SLE patients. The results showed that belimumab significantly improved joint and skin symptoms and reduced the use of glucocorticoids. A significant proportion of patients who did not achieve complete remission initially achieved remission during follow-up.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Article Medicine, General & Internal

Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study

Sebastiano Cicco, Marialuisa Sveva Marozzi, Carmen Alessandra Palumbo, Elisabetta Sturda, Antonio Fusillo, Flavio Scarilli, Federica Albanese, Claudia Morelli, Davide Fiore Bavaro, Lucia Diella, Annalisa Saracino, Fabrizio Pappagallo, Antonio Giovanni Solimando, Gianfranco Lauletta, Roberto Ria, Angelo Vacca

Summary: Lung ultrasound (LUS) can effectively evaluate and follow lung involvement in COVID-19 patients, and early treatment leads to better recovery and reduced lung involvement after three months.

MEDICINA-LITHUANIA (2023)

Article Medicine, General & Internal

A Challenging Case of Visceral Leishmaniasis

Antonio Giovanni Solimando, Giuseppe Coniglio, Vanessa Desantis, Gianfranco Lauletta, Davide Fiore Bavaro, Lucia Diella, Anna Cirulli, Giuseppe Iodice, Piero Santoro, Sebastiano Cicco, Giuseppe Ingravallo, Fabio Signorile, Roberto Ria, Monica Montagnani, Annalisa Saracino, Angelo Vacca

Summary: Leishmaniasis is a disease caused by parasitic infection, with various clinical syndromes depending on the site of infection. The disease phenotype is mainly determined by the biological characteristics of the parasite and the host's immune status.

REPORTS (2022)

暂无数据